Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Open accessThe DOI matches its Crossref record; 340 of the 344 references it cites were found in a registry or an index.
Abstract
Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular complications, which represent the major cause of mortality. Despite effective treatment of established cardiovascular (CV) risk factors (dyslipidemia, hypertension, procoagulant state), there remains a significant amount of unexplained CV risk. Insulin resistance is associated with a cluster of cardiometabolic risk factors known collectively as the insulin resistance (metabolic) syndrome (IRS). Considerable evidence, reviewed herein, suggests that insulin resistance and the IRS contribute to this unexplained CV risk in patients with T2DM. Accordingly, CV outcome trials with pioglitazone have demonstrated that this insulin-sensitizing thiazolidinedione reduces CV events in high-risk patients with T2DM. In this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, as the MAPK pathway has normal sensitivity to insulin, hyperinsulinemia activates the MAPK pathway, promoting vascular smooth muscle cell growth and activating inflammatory pathways, such as IkB/NF-kB and JNK [107,108].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [108]
In the citing paper
“These macrophages, in combination with adipocytes and lipid-infiltrated muscle tissues, stimulate the secretion of proinflammatory cytokines, particularly TNF-α and IL-6, while reducing the release of protective adiponectin, thereby evoking systemic chronic inflammation that directly damages the vascular endothelium and, in, turn exacerbates IR and atherosclerosis (56).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [56]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Research works printed but not linked: 1
- Hsueh, 1999, Insulin signals in the arterial wall, J Cardiol, 84, 21, 10.1016/S0002-9149(99)00353-7 · DOI · Paper page
Cited by
Ding, X., Wang, X., Wu, J., Zhang, M., & Cui, M. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01268-9 · Cited by 454
“Pathophysiologically, the current results reflect the previously suggested role of insulin resistance in the pathogenesis of atherosclerosis [8, 10].”
BackgroundInsulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 385
Hong, S.-H., & Choi, K. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020494 · Cited by 390
“MAPK Family JNK is a member of the MAPK family and is activated by TNF-α, IL-1β, free-fatty acids, ER stress, and LTB4 [66,67].”
BackgroundInfluentialHong, S., Han, K., & Park, C.-Y. (2020) · BMC Medicine · doi:10.1186/s12916-020-01824-2 · Cited by 376
Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management
Wei, S., Nguyen, T. T., Zhang, Y., Ryu, D., & Gariani, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1185221 · Cited by 291
Metadata
- Authors
- Di Pino, A., & DeFronzo, R. A.
- Affiliations
- Diabetes Division, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A
- ORCID
- DeFronzo, Ralph A
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2019-05-03
- Volume
- 40
- Issue
- 6
- Pages
- 1447-1467
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7445419
- OpenAlex
- W2945554427
- Cited by
- 535
- References
- 344
- Citations by year
- 2026: 77 · 2025: 117 · 2024: 95 · 2023: 76 · 2022: 89 · 2021: 55 · 2020: 22 · 2019: 4
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (DK-24092-38)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin resistance, atherosclerosis, type 2 diabetes, metabolic syndrome, insulin sensitizers, thiazolidinediones, pioglitazone, cardiovascular risk, macrovascular complications, cardiovascular outcome trials, antihyperglycemic medications, cardiometabolic risk factors
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Thiazolidinediones, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. https://app.cochat.ai/papers/10.1210/er.2018-00141
- The paper
- Di Pino, A., & DeFronzo, R. A. (2019). Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. Endocrine Reviews. https://doi.org/10.1210/er.2018-00141
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.